Don’t wait to get started
Don’t wait to get started
Don’t wait to get started
NEW PRODUCTS VIRUS DETECTION ANTIBODY DEVELOPMENT RESOURCES
NEW PRODUCTS

The recent Coronavirus pandemic has led to a rapid response from the viral research and therapeutics community around the world.  These research teams need robust and reliable genomic tools to classify and characterize viral samples, and genome engineering tools to build vaccines to help stop the spread of this deadly virus.  

Twist’s unique silicon-based DNA writing platform allows for the rapid development of NGS panels for viral detection and characterization of samples, and our Clonal Genes and Gene Fragments allow for quick development of subunit vaccines from one or more antigen-presenting viral genes or peptide sequences, which bypasses the need for scientists to handle live and potentially dangerous pathogens, and minimizes the time needed to clone DNA fragments.

COVID-19 Antibodies

Antibodies targeting the SARS-CoV-2 Spike Protein and human ACE2 have been developed using Twist Biopharma’s variant library generation and screening capabilities. Data and information about these antibodies can be found at the link below. 

Antibodies for COVID-19

Respiratory Virus Research Panel

The Twist Respiratory Virus Research Panel allows for detection of multiple viral pathogens from a single sample, detecting as little as 100 copies of viral material per virus. Coupled with analysis by One Codex, researchers can generate reports with viral species identification and create publication-ready visualizations.

Products:
Related Resources:

Respiratory Virus Controls

The Twist Respiratory Virus Controls enable investigation into the biology of a broad range of viruses by NGS and qPCR. Included in the panel is a range of variants with comprehensive coverage of full length synthetic virus sequences, enabling distinction between key infectious agents.

Related Resources:

ORder Now

Synthetic SARS-CoV-2 RNA Controls

Positive controls provide quality control measures for the verification and validation for point-of-care diagnostic tests including both next-generation sequencing (NGS) and reverse transcriptase-polymerase chain reaction (RT-PCR) assays. Twist offers fully synthetic SARS-CoV-2 RNA controls, available for 7 distinct reference sequences.

Products:
Related Resources:

SARS-CoV-2 Research Panels

In addition to the robust RNA standards, Twist also offers Research-Use Only (RUO) target enrichment NGS panels for viral detection and characterization of samples. These panels can be used for environmental monitoring and surveillance testing, while also providing insight into full sequence information for monitoring of viral evolution and strain origin.

Products:
Related Resources:

To order these products please click button below and be sure to sign up for an account or login to our online ordering platform.

order Now

 

Additional Resources:

Read our latest blog post on Building the Raw Materials to Tackle Coronavirus

Watch now: Why labs are printing the Coronavirus genome

 

WRITING THE FUTURE OF COVID-19 THERAPIES

Learn about how Dr. Aaron Sato Twist’s CSO and leader of our Biopharma division is building antibody therapeutics to address COVID-19 infection.

Watch the Webinar

Twist COVID-19 antibody for therapeatic and diagnostic development

The recent Coronavirus pandemic has led to a rapid response from the viral research and therapeutics community around the world.  These research teams need robust and reliable genomic tools to classify and characterize viral samples, and genome engineering tools to build vaccines to help stop the spread of this deadly virus.  

Twist’s unique silicon-based DNA writing platform allows for the rapid development of NGS panels for viral detection and characterization of samples, and our Clonal Genes and Gene Fragments allow for quick development of subunit vaccines from one or more antigen-presenting viral genes or peptide sequences, which bypasses the need for scientists to handle live and potentially dangerous pathogens, and minimizes the time needed to clone DNA fragments.

COVID-19 Antibodies

Antibodies targeting the SARS-CoV-2 Spike Protein and human ACE2 have been developed using Twist Biopharma’s variant library generation and screening capabilities. Data and information about these antibodies can be found at the link below. 

Antibodies for COVID-19

Respiratory Virus Research Panel

The Twist Respiratory Virus Research Panel allows for detection of multiple viral pathogens from a single sample, detecting as little as 100 copies of viral material per virus. Coupled with analysis by One Codex, researchers can generate reports with viral species identification and create publication-ready visualizations.

Products:
Related Resources:

Respiratory Virus Controls

The Twist Respiratory Virus Controls enable investigation into the biology of a broad range of viruses by NGS and qPCR. Included in the panel is a range of variants with comprehensive coverage of full length synthetic virus sequences, enabling distinction between key infectious agents.

Related Resources:

ORder Now

Synthetic SARS-CoV-2 RNA Controls

Positive controls provide quality control measures for the verification and validation for point-of-care diagnostic tests including both next-generation sequencing (NGS) and reverse transcriptase-polymerase chain reaction (RT-PCR) assays. Twist offers fully synthetic SARS-CoV-2 RNA controls, available for 7 distinct reference sequences.

Products:
Related Resources:

SARS-CoV-2 Research Panels

In addition to the robust RNA standards, Twist also offers Research-Use Only (RUO) target enrichment NGS panels for viral detection and characterization of samples. These panels can be used for environmental monitoring and surveillance testing, while also providing insight into full sequence information for monitoring of viral evolution and strain origin.

Products:
Related Resources:

To order these products please click button below and be sure to sign up for an account or login to our online ordering platform.

order Now

 

Additional Resources:

Read our latest blog post on Building the Raw Materials to Tackle Coronavirus

Watch now: Why labs are printing the Coronavirus genome

 

WRITING THE FUTURE OF COVID-19 THERAPIES

Learn about how Dr. Aaron Sato Twist’s CSO and leader of our Biopharma division is building antibody therapeutics to address COVID-19 infection.

Watch the Webinar

Twist COVID-19 antibody for therapeatic and diagnostic development

VIRUS DETECTION

Antibodies for COVID-19 Diagnostic Development

The Twist anti-SARS-CoV-2 antibody collection exhibits high binding affinity and specificity to the spike protein of the novel coronavirus. These potent antibodies can be used in the development of a variety of diagnostic testing methods aimed at the detection of SARS-CoV-2 infection. Contact us to learn more.

Products:
Related Resources:

NGS for Virus Detection

Next-generation sequencing (NGS) offers high-throughput, specific identification of infections in blood samples. In the case of viral infections, however, obtaining genetic material sufficient for sequencing can be a challenge due to the extremely low levels of virus often present. In these situations, target enrichment which uses DNA-based hybridization probes to isolate specific sequences out of a mixed genomic sample can increase the sensitivity and specificity of NGS-based efforts.

 

Custom Panels and Kits

Twist has been working with the viral research community to build NGS TE panels to screen for and characterize this novel coronavirus strain.  Please contact us to access this panel content or to build a custom panel targeting your specific gene set.


Let's Talk

Antibodies for COVID-19 Diagnostic Development

The Twist anti-SARS-CoV-2 antibody collection exhibits high binding affinity and specificity to the spike protein of the novel coronavirus. These potent antibodies can be used in the development of a variety of diagnostic testing methods aimed at the detection of SARS-CoV-2 infection. Contact us to learn more.

Products:
Related Resources:

NGS for Virus Detection

Next-generation sequencing (NGS) offers high-throughput, specific identification of infections in blood samples. In the case of viral infections, however, obtaining genetic material sufficient for sequencing can be a challenge due to the extremely low levels of virus often present. In these situations, target enrichment which uses DNA-based hybridization probes to isolate specific sequences out of a mixed genomic sample can increase the sensitivity and specificity of NGS-based efforts.

 

Custom Panels and Kits

Twist has been working with the viral research community to build NGS TE panels to screen for and characterize this novel coronavirus strain.  Please contact us to access this panel content or to build a custom panel targeting your specific gene set.


Let's Talk

ANTIBODY DEVELOPMENT

Antibodies for COVID-19 Therapeutic and Diagnostic Development

The Twist Biopharma team is excited to announce the launch of two panels of antibodies with specificity against SARS-CoV-2 S or human ACE2 proteins. The SARS-CoV-2 Spike Protein panel and the ACE2 antibody panel consist of sets of individual recombinant human antibody clones that show very high specificity and binding affinities to their targets with many in the picomolar to nanomolar range.

All antibodies are cloned into human antibody backbones to generate VHH Fc, IgG1 or IgG2 antibodies. The SARS-CoV-2 S panel consists of 32 individual clones, while the human ACE2 proteins panel has 48 individual clones.
We are excited to collaborate with you to move these molecules to the next level in an effort to solve this global pandemic.

Products:
Related resources:

Genes for Vaccine Development

Twist’s unique silicon-based DNA writing platform allows for unprecedented speed and scale of development of customized research tools to address this rapid moving epidemic.

Twist’s double-stranded DNA Gene fragments can be used to create synthetic proteins designed as safe reagents for vaccine research. 

Twist also offers Customized Cloned Genes available in a variety of vectors.
 

Order Now
 

Writing the Future of COVID-19 Therapies

Learn about how Dr. Aaron Sato Twist’s CSO and leader of our Biopharma division is building antibody therapeutics to address COVID-19 infection.

Watch the Webinar

Twist COVID-19 Antibodies

Antibodies for COVID-19 Therapeutic and Diagnostic Development

The Twist Biopharma team is excited to announce the launch of two panels of antibodies with specificity against SARS-CoV-2 S or human ACE2 proteins. The SARS-CoV-2 Spike Protein panel and the ACE2 antibody panel consist of sets of individual recombinant human antibody clones that show very high specificity and binding affinities to their targets with many in the picomolar to nanomolar range.

All antibodies are cloned into human antibody backbones to generate VHH Fc, IgG1 or IgG2 antibodies. The SARS-CoV-2 S panel consists of 32 individual clones, while the human ACE2 proteins panel has 48 individual clones.
We are excited to collaborate with you to move these molecules to the next level in an effort to solve this global pandemic.

Products:
Related resources:

Genes for Vaccine Development

Twist’s unique silicon-based DNA writing platform allows for unprecedented speed and scale of development of customized research tools to address this rapid moving epidemic.

Twist’s double-stranded DNA Gene fragments can be used to create synthetic proteins designed as safe reagents for vaccine research. 

Twist also offers Customized Cloned Genes available in a variety of vectors.
 

Order Now
 

Writing the Future of COVID-19 Therapies

Learn about how Dr. Aaron Sato Twist’s CSO and leader of our Biopharma division is building antibody therapeutics to address COVID-19 infection.

Watch the Webinar

Twist COVID-19 Antibodies

RESOURCES

Twist Product Information

Twist is launch tools to address the growing SARS-CoV-2 pandemic.

We will continue to provide product updates as they become available. You may access the latest information from these links:

FDA Information on Diagnostic Testing

The information related to SARS-CoV-2 pandemic is rapidly evolving.

The FDA is providing continual updates and you may access the latest information from these links:

CDC Information for research labs

The information related to SARS-CoV-2 pandemic is rapidly evolving.

The CDC is providing continual updates and you may access the latest information from these links:

Twist Product Information

Twist is launch tools to address the growing SARS-CoV-2 pandemic.

We will continue to provide product updates as they become available. You may access the latest information from these links:

FDA Information on Diagnostic Testing

The information related to SARS-CoV-2 pandemic is rapidly evolving.

The FDA is providing continual updates and you may access the latest information from these links:

CDC Information for research labs

The information related to SARS-CoV-2 pandemic is rapidly evolving.

The CDC is providing continual updates and you may access the latest information from these links: